Effects of Bifidobacterium and rosuvastatin on metabolic-associated fatty liver disease via the gut–liver axis
Abstract Background/aims Research has indicated that treatment with rosuvastatin can improve liver pathology in metabolic-associated fatty liver disease (MAFLD) patients and that treatment with Bifidobacterium can improve MAFLD. Therefore, the effects of Bifidobacterium, rosuvastatin, and their comb...
Saved in:
| Main Authors: | Xue Ran, Ying-jie Wang, Shi-gang Li, Chi-bing Dai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-024-02391-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bifidobacterium breve alleviates gut-liver-axis injury caused by high-fat diet and aflatoxin B1 in mice
by: Yongli Ye, et al.
Published: (2025-02-01) -
Effect of Bifidobacterium animalis subsp. lactis Bi66 on Alleviating Constipation and Regulating Gut Microbiota
by: Zhixian CHEN, et al.
Published: (2025-04-01) -
Unravelling the gut-liver axis: The role of gut microbiota-mitochondria interactions in the pathogenesis and management of metabolic-associated fatty liver disease (MAFLD)
by: Binzhi Zhang, et al.
Published: (2025-03-01) -
Bifidobacterium depletion promotes goiter via gut-thyroid axis: evidence from Mendelian randomization and experimental validation
by: Wenyong Liao, et al.
Published: (2025-07-01) -
Probiotic Bifidobacterium reduces serum TMAO in unstable angina patients via the gut to liver to heart axis
by: Zhihong Zhou, et al.
Published: (2025-03-01)